Hints and tips:
Related Special Reports
...Because the European market is saturated with the BioNTech/Pfizer and Moderna shots, it remains unclear what impact on its revenues an approval might have....
...“If [BioNTech/Pfizer] supply around 70mn doses per year for the next few years, that’s pretty much the totality of the market,” said one person familiar with the negotiations....
...A person familiar with the process said Merck “understood there was no hope . . . [Lagevrio] is a bit burnt”....
...Last week, a verdict was passed down in the case of Walkers Snack Foods Ltd v Commissioners for His Majesty’s Revenue and Customs, with first-tier tribunal judges Anne Fairpo and Sonia Gable ruling against...
...A person familiar with the EMA approval process said at the time that the drug had been “a bit of a disappointment” and that 30 per cent efficacy “started to be on the limits of [what is considered] benefit...
...Approval could come as early as this week, according to a person familiar with the matter, who added that this would play an important role on the future of the contract....
...Given the EMA guidance, Pfizer thinks it is only fair to fulfil its contractual obligations with European countries and use the remaining doses to supply the developing world, according to a person familiar...
...his home office around that time, Mr Loeb had explained how, as a result of the firm’s research and use of data providers, he was not overly worried about the effect of the election on markets, said a person...
...A version of this article was first published by Nikkei Asia on February 14 2023. ©2023 Nikkei Inc. All rights reserved....
...A 25 per cent premium to the estimated value of the business — which would push a bid above £60bn — would warrant serious consideration from the board, according to one person close to Pfizer....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...A normal person can’t afford a Lamborghini....
...their life on hold because they have been unable to be vaccinated and there is not enough vaccine uptake in the population above 12 years [of age] to prevent cases recognised in schools from disrupting in-person...
...“Countries reported to us that they had been trying to get hold of Pfizer and no one returned their calls,” says a person familiar with the African Union’s vaccine-purchasing operation....
...“If you don’t have a test sitting in your cupboard waiting to be used then how many days does the average person go from the moment they have a sniffle to actually getting off their butts and getting a test...
...The Pfizer vaccine was the first to be authorised in the US for use in adolescents over the age of 12....
...The BioNTech/Pfizer jab will be dispensed in “kid-sized” doses, a third of the size of those for people aged 12 years and more....
...Third doses will be available six months after full vaccination only for people who initially received BioNTech/Pfizer jabs....
...A person familiar with the EMA’s approval process told the Financial Times the drug had been “a bit of a disappointment” and that 30 per cent efficacy “started to be on the limits of [what is considered]...
...The booster has been authorised to be administered at least six months after a person is fully vaccinated....
...They will also discuss the results of a preliminary study of a US trial on mixing Covid-19 vaccines as part of a booster programme — a practice that some experts believe could boost a person’s immune response...
...Top of the league table is Canada with 8.8 doses per person, followed by the UK which ordered seven. The UK’s stockpile will not be as big as expected, though....
...That panel has been told to expect a meeting to discuss vaccinating 12- to 15-year-olds with the Pfizer jab next week, according to a person aware of the plans....
...Vaccinating children could instil greater confidence in a mass return to classrooms, with many schools currently providing a mix of in-person and online learning....
...In a memo to staff seen by the Financial Times, Bastian said the average cost to Delta for an employee’s Covid-related hospitalisation was $40,000 per person and that all of its infected workers in recent...
International Edition